Genmab As Stock Performance

GMAB Stock  USD 21.30  0.38  1.82%   
Genmab AS has a performance score of 3 on a scale of 0 to 100. The company retains a Market Volatility (i.e., Beta) of 0.0793, which attests to not very significant fluctuations relative to the market. As returns on the market increase, Genmab AS's returns are expected to increase less than the market. However, during the bear market, the loss of holding Genmab AS is expected to be smaller as well. Genmab AS right now retains a risk of 2.24%. Please check out Genmab AS skewness, rate of daily change, and the relationship between the value at risk and accumulation distribution , to decide if Genmab AS will be following its current trending patterns.

Risk-Adjusted Performance

Insignificant

 
Weak
 
Strong
Compared to the overall equity markets, risk-adjusted returns on investments in Genmab AS are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat strong basic indicators, Genmab AS is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more

Actual Historical Performance (%)

One Day Return
1.82
Five Day Return
12.88
Year To Date Return
1.43
Ten Year Return
187.84
All Time Return
464.99
Last Split Factor
5:1
Last Split Date
2018-05-01
JavaScript chart by amCharts 3.21.1512345678910Dec2025Feb -15-10-50
JavaScript chart by amCharts 3.21.15Genmab AS Genmab AS Dividend Benchmark Dow Jones Industrial
1
Genmab to Present at Citis Global Healthcare Conference
11/25/2024
2
Genmab to Hold 2024 RD Update and ASH Data Review Meeting
12/11/2024
3
GMAB vs. QGEN Which Stock Is the Better Value Option
01/16/2025
4
Genmab says net sales of DARZALEX in 2024 totalled 11.67B
01/22/2025
5
Genmab grants stock units and warrants to employees
01/23/2025
6
Genmabs SWOT analysis biotech firms stock faces growth and integration challenges
01/24/2025
7
Genmab AS Reaches New 52-Week Low Time to Sell
01/29/2025
8
R Squared Ltd Acquires New Holdings in Genmab AS
01/31/2025
9
Genmab AS Releases Quarterly Earnings Results, Beats Estimates By 0.29 EPS
02/12/2025
10
Ingalls Snyder LLC Has 2.84 Million Stock Position in Genmab AS
02/13/2025
Begin Period Cash Flow9.9 B
  

Genmab AS Relative Risk vs. Return Landscape

If you would invest  2,050  in Genmab AS on November 19, 2024 and sell it today you would earn a total of  80.00  from holding Genmab AS or generate 3.9% return on investment over 90 days. Genmab AS is currently generating 0.0875% in daily expected returns and assumes 2.2365% risk (volatility on return distribution) over the 90 days horizon. In different words, 19% of stocks are less volatile than Genmab, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
JavaScript chart by amCharts 3.21.15CashMarketGMAB 0.00.51.01.52.02.5 -0.04-0.020.000.020.040.060.080.10
       Risk  
Given the investment horizon of 90 days Genmab AS is expected to generate 3.12 times more return on investment than the market. However, the company is 3.12 times more volatile than its market benchmark. It trades about 0.04 of its potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.07 per unit of risk.

Genmab AS Market Risk Analysis

Today, many novice investors tend to focus exclusively on investment returns with little concern for Genmab AS's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Genmab AS, and traders can use it to determine the average amount a Genmab AS's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.

Sharpe Ratio = 0.0391

Best PortfolioBest Equity
Good Returns
Average Returns
Small Returns
CashSmall RiskGMABHigh RiskHuge Risk
Negative Returns

Estimated Market Risk

 2.24
  actual daily
19
81% of assets are more volatile

Expected Return

 0.09
  actual daily
1
99% of assets have higher returns

Risk-Adjusted Return

 0.04
  actual daily
3
97% of assets perform better
Based on monthly moving average Genmab AS is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Genmab AS by adding it to a well-diversified portfolio.

Genmab AS Fundamentals Growth

Genmab Stock prices reflect investors' perceptions of the future prospects and financial health of Genmab AS, and Genmab AS fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Genmab Stock performance.
Return On Equity0.23
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-200%-150%-100%-50%
Return On Asset0.11
Profit Margin0.36 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-120%-100%-80%-60%-40%-20%
Operating Margin0.35 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-120%-100%-80%-60%-40%-20%
Current Valuation10.59 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%5,000%
Shares Outstanding635.4 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Price To Earning66.53 X
Price To Book2.65 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%
Price To Sales0.63 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%150%
Revenue16.47 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-315,000%10,000%15,000%20,000%25,000%30,000%
Gross Profit20.54 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%5,000%10,000%15,000%20,000%25,000%
EBITDA5.56 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-200%0%200%400%600%800%1,000%
Net Income5.64 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-1,200%-1,000%-800%-600%-400%-200%0%
Cash And Equivalents21.61 B
Cash Per Share33.05 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%3,000%3,500%
Total Debt770 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%1,000%2,000%3,000%4,000%5,000%6,000%
Debt To Equity0.03 %
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-100%-50%0%50%100%150%
Current Ratio13.11 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-50%0%50%100%
Book Value Per Share577.54 X
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%100%200%300%400%500%600%
Cash Flow From Operations7.38 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-3,000%-2,500%-2,000%-1,500%-1,000%-500%0%
Earnings Per Share1.69 X
Market Capitalization13.53 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-311,000%2,000%3,000%4,000%5,000%
Total Asset35.29 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-310%500%1,000%1,500%2,000%2,500%
Retained Earnings19.02 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31-3,000%-2,000%-1,000%0%
Working Capital30.66 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31
Current Asset12.65 B
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%2,000%2,500%
Current Liabilities823.51 M
JavaScript chart by amCharts 3.21.152011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-31500%1,000%1,500%

About Genmab AS Performance

By analyzing Genmab AS's fundamental ratios, stakeholders can gain valuable insights into Genmab AS's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Genmab AS has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Genmab AS has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Last ReportedProjected for Next Year
Days Of Inventory On Hand 105.87  192.91 
Return On Tangible Assets 0.11  0.12 
Return On Capital Employed 0.16  0.15 
Return On Assets 0.11  0.12 
Return On Equity 0.12  0.13 

Things to note about Genmab AS performance evaluation

Checking the ongoing alerts about Genmab AS for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Genmab AS help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Genmab AS has a strong financial position based on the latest SEC filings
Latest headline from thelincolnianonline.com: Ingalls Snyder LLC Has 2.84 Million Stock Position in Genmab AS
Evaluating Genmab AS's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Genmab AS's stock performance include:
  • Analyzing Genmab AS's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Genmab AS's stock is overvalued or undervalued compared to its peers.
  • Examining Genmab AS's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Genmab AS's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Genmab AS's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Genmab AS's stock. These opinions can provide insight into Genmab AS's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Genmab AS's stock performance is not an exact science, and many factors can impact Genmab AS's stock market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Genmab Stock analysis

When running Genmab AS's price analysis, check to measure Genmab AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genmab AS is operating at the current time. Most of Genmab AS's value examination focuses on studying past and present price action to predict the probability of Genmab AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genmab AS's price. Additionally, you may evaluate how the addition of Genmab AS to your portfolios can decrease your overall portfolio volatility.
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio Center
All portfolio management and optimization tools to improve performance of your portfolios
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Technical Analysis
Check basic technical indicators and analysis based on most latest market data
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Efficient Frontier
Plot and analyze your portfolio and positions against risk-return landscape of the market.
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine